主转录因子重编程释放选择性翻译促进致死性前列腺癌的去势抵抗与免疫逃逸
研究揭示致死性前列腺癌中MITF下调解除对eIF3B的抑制,eIF3B依赖的选择性翻译上调雄激素受体和MHC-I,导致去势抵抗和免疫逃逸;临床前模型中药理靶向eIF3B依赖翻译可增敏ADT和抗PD-1治疗。
要点
- MITF下调通过直接启动子结合解除对eIF3B的抑制,驱动翻译重编程。
- eIF3B通过5'UTR的UC富集基序选择性翻译雄激素受体和MHC-I。
- 临床前模型中药理靶向eIF3B依赖翻译可增敏ADT和抗PD-1治疗。
核心结论
- 致死性前列腺癌中MITF下调释放eIF3B依赖的特定mRNA翻译,赋予去势抵抗和免疫逃逸。
- 药理靶向该机制可延缓去势抵抗并增强免疫检查点疗效。
研究设计与样本
- 临床前研究,结合eCLIP-seq全基因组分析及药理学干预模型。
主要发现
- MITF通过直接启动子结合抑制eIF3B,eIF3B进而调控特定mRNA的翻译。
- eIF3B对5'UTR中UC富集基序显示特异性结合。
- 雄激素受体和MHC-I的翻译通过该基序受eIF3B水平影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Signaling rewiring allows tumors to survive therapy. Here we show that the decrease of the master regulator microphthalmia transcription factor (MITF) in lethal prostate cancer unleashes eukaryotic initiation factor 3B (eIF3B)-dependent translation reprogramming of key mRNAs conferring resistance to androgen deprivation therapy (ADT) and promoting immune evasion. Mechanistically, MITF represses through direct promoter binding eIF3B, which in turn regulates the translation of specific mRNAs. Genome-wide eIF3B enhanced cross-linking immunoprecipitation sequencing (eCLIP-seq) showed specialized binding to a UC-rich motif present in subsets of 5' untranslated regions. Indeed, translation of the androgen receptor and major histocompatibility complex I (MHC-I) through this motif is sensitive to eIF3B amount. Notably, pharmacologic targeting of eIF3B-dependent translation in preclinical models sensitizes prostate cancer to ADT and anti-PD-1 therapy. These findings uncover a hidden connection between transcriptional and translational rewiring promoting therapy-refractory lethal prostate cancer and provide a druggable mechanism that may transcend into effective combined therapeutic strategies. SIGNIFICANCE: Our study shows that specialized eIF3B-dependent translation of specific mRNAs released upon downregulation of the master transcription factor MITF confers castration resistance and immune evasion in lethal prostate cancer. Pharmacologic targeting of this mechanism delays castration resistance and increases immune-checkpoint efficacy. This article is featured in Selected Articles from This Issue, p. 2489.
引用
- Santasusagna S, Zhu S, Jawalagatti V, et al. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer Discov. 2023. PMID: 37676710. doi:10.1158/2159-8290.CD-23-0306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。